Provided by Tiger Fintech (Singapore) Pte. Ltd.

Assembly Biosciences

18.75
+0.53002.91%
Post-market: 18.750.00000.00%19:07 EDT
Volume:30.25K
Turnover:565.04K
Market Cap:143.20M
PE:-3.06
High:19.11
Open:18.24
Low:18.24
Close:18.22
Loading ...

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

GlobeNewswire
·
09 Apr

Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround

Zacks
·
08 Apr

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
27 Mar

Assembly Biosciences Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $31

THOMSON REUTERS
·
25 Mar

Assembly Biosciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
22 Mar

BRIEF-Assembly Biosciences Inc Files For Mixed Shelf Offering Of Up To $250 Million

Reuters
·
21 Mar

BRIEF-Assembly Biosciences FY Net Income USD 40.177 Million

Reuters
·
21 Mar

Assembly Biosciences files $250M mixed securities shelf

TIPRANKS
·
21 Mar

Assembly Biosciences FY 2024 GAAP EPS $(6.69) Beats $(7.54) Estimate, Sales $28.520M Beat $26.838M Estimate

Benzinga
·
21 Mar

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

THOMSON REUTERS
·
21 Mar

Assembly Biosciences FY Income From Operations USD -45.42 Million

THOMSON REUTERS
·
21 Mar

Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Dow Jones
·
21 Mar

Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?

Insider Monkey
·
05 Mar

Assembly Biosciences Doses First Subject in Phase 1a Trial of Hepatitis Delta Virus Therapy Candidate; Shares Up

MT Newswires Live
·
26 Feb

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate Abi-6250 for Hepatitis Delta Virus

THOMSON REUTERS
·
26 Feb

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

GlobeNewswire
·
26 Feb

ADVISORY-Alert on executive appointment wrongly tagged to Assembly Biosciences withdrawn

Reuters
·
08 Jan

Kacper KŁOs Named CEO of Assembly Digital Commerce

THOMSON REUTERS
·
08 Jan

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barron's

Dow Jones
·
04 Jan